650 results about "Lipoprotein" patented technology

Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaecnoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].

The present invention provides methods for identifying various biological states. Methods for diagnosis of diseases, in particular cardiovascular and brain diseases, are provided herein. One aspect of the invention is the analysis of lipoprotein complexes with summary survey scan mass spectrum for the analysis of biological states. Another aspect of the invention is the use of matrix assisted laser desorption ionization (MALDI) mass spectrometer to analysis lipoprotein complexes for the diagnosis of cardiovascular and brain diseases. Yet another aspect of the invention is a method of diagnosis of brain diseases by evaluating the characteristics of lipoprotein complexes.

Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.

The present invention provides a sensor that electrochemically determines cholesterol in low density lipoprotein by only one feed of a sample. The sensor has: an electrode system that is mounted on an electrically insulating base plate and includes at least a working electrode and a counter electrode; an enzyme layer formed on the base plate with the electrode system; and a reagent layer that is arranged before the enzyme layer in a sample solution supply path to the electrode system. The enzyme layer includes at least an oxidoreductase and an electron mediator. The reagent layer includes a reagent that depresses reactivity of cholesterol in lipoproteins other than the low density lipoprotein with the oxidoreductase, for example, a reagent that attaches to lipoproteins other than the low density lipoprotein to form a water-soluble complex.

Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaenoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].

The invention concerns compositions and methods for assay or detection of apolipoprotein-B48 in samples. In particular, it concerns a method for differential measurement of apolipoprotein-B48 (“Apo-B48”) and apolipoprotein-B100 (“Apo-B100”) in biological samples. The invention also concerns synthetic products of Apo-B100, the corresponding antibodies, kits containing same, and their uses for detecting, differentially quantifying and / or recording an amount of Apo-B48 and / or Apo-B100 in a sample, or for quantifying and / or recording atherogenic lipoparticles in a sample. The products, materials and kits hereinabove can also be used for differentially modulating the levels of Apo-B48 and / or Apo-B100 or their activity, in vitro or in vivo, and for regulating lipid metabolism in a subject.

Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron / lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

A multilayer test strip that measures concentrations of multiple analytes from a single whole blood sample. The test strip includes a test matrix of several layers held together in constant contact by a test strip holder. The invention is characterized in that it has no moving parts, which is made possible by the novel use of an elongate disbursement layer that spreads blood throughout its entire length, despite having layers with known wicking properties adjacent to and in contact with it. Since the invention relies primarily on a vertical flow format, the test strip is advantageously quite compact. With a single 35 microliter sample of blood applied thereto, the novel test strip can provide readings of total cholesterol, HDL cholesterol and triglycerides. From these, LDL can be calculated, thereby providing a full “lipid panel.” Other analytes such as glucose and ketones may be included in the test strip in addition to or in lieu of one or more of the other analytes.

A medical diagnostic method and instrumentation system for analyzing noncovalently bonded agglomerated biological particles is described. The method and system comprises: a method of preparation for the biological particles; an electrospray generator; an alpha particle radiation source; a differential mobility analyzer; a particle counter; and data acquisition and analysis means. The medical device is useful for the assessment of human diseases, such as cardiac disease risk and hyperlipidemia, by rapid quantitative analysis of lipoprotein fraction densities. Initially, purification procedures are described to reduce an initial blood sample to an analytical input to the instrument. The measured sizes from the analytical sample are correlated with densities, resulting in a spectrum of lipoprotein densities. The lipoprotein density distribution can then be used to characterize cardiac and other lipid-related health risks.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

A medical risk assessment method and computer program product resident on a computer or a hand-held device that allows a physician to determine the best strategy for primary and secondary cardiovascular disease prevention utilizing current guidelines and published medical literature. The computer program product evaluates a number of risk factors to determine specific recommendations for an individual patient, including Framingham risk scoring (FRS), pertinent medical history, individual lipid panel and advanced lipoprotein profiling, patient laboratory test results, and published literature on the effects of anti-lipid medicines on plasma concentration and / or composition of lipoprotein molecules and clinical outcomes. The risk assessment method establishes a cardiovascular treatment therapy strategy for a patient by determining a cardiac risk classification group, determining a cardiovascular treatment therapy based on the patient's lipoprotein profile and the patient's cardiac group risk classification, and presenting the cardiovascular treatment therapy for the patient to a medical practitioner on a patient evaluation display.

This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and / or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.

Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and / or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins / invasins.

The disclosure describes methods, systems, and devices for analysis of lipoproteins and for diagnosing and / or determining risk of cardiovascular disease. In some embodiments, lipoproteins are separated by electrophoretically using a micro-channel device, and the data are analyzed using an adaptive method such as a neural network.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp (a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and / or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

The invention discloses a composition of probiotic fermented horseradish tree leaves as well as a preparation method and application of the composition. The preparation method comprises the following steps: crushing and immersing horseradish tree leaves; adding glucose, peptone, yeast extract, yeast powder and inorganic salt into an immersing solution; extracting at a high pressure; and after carrying out probiotic fermentation and centrifuging, adding polydextrose and fructo-oligosaccharide syrup and sterilizing to obtain the composition of the probiotic fermented horseradish tree leaves. The composition can be used for preparing health products, foods and beverages capable of lowering blood fat and improving a sleeping function. An experiment shows that the composition of the probiotic fermented horseradish tree leaves can be used for reducing the contents of total cholesterol (TC) and triglyceride (TG) in blood serum, and improving the content of high density lipoprotein cholesterol (HDL-C) in the blood serum; the composition of the probiotic fermented horseradish tree leaves, disclosed by the invention, has a function of lowering a blood fat level.

The present invention relates to a composition and method for activating an antigen specific immune response using by providing a host with a native low density lipoprotein and a nucleic acid that expressed an antigen bound to the low density lipoprotein.

Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.

The invention provides an oligosaccharide oat beverage capable of treating hyperlipoidemia and hyperglycemia and improving gastrointestinal tract function and a manufacturing method thereof by hydrolysis of three enzymes and fine grinding. The manufacturing method comprises the following steps: carrying out fine grinding on the oat meal to obtain the powder of which the average particle size is less than about 100 mu m, dissolving the oat powder in water to form oat slurry, and adding alpha-amylase, beta-amylase and trans-glucosidase to carry out enzyme treatment, thereby obtaining the oat beverage with rich functional components. The oligosaccharide oat beverage integrally reserves oat beta-dextran, and also contains oligo-isomaltose component of which the content is higher than that in common oat products. The manufacturing method can integrally reserve the nutritional components of the whole oat grains and omit the filter operation, thereby being beneficial to increasing the utilization ratio of raw materials; and the method is completed under the conditions of fermentation and sterilization in the optimal short time, thereby avoiding the possibility of rancidity of oat slurry in the processing procedure. When the oligosaccharide oat beverage is used for human testing for assessing physiologic effect, the test proves that the oligosaccharide oat beverage can lower the total cholesterol, low-density lipoprotein cholesterol, triglyceride and fasting blood-glucose value in blood. The oligosaccharide oat beverage tastes savoury, thick and smooth like milk, and maintains the natural flavor of oat; and thus, the invention changes the traditional way for eating oat, greatly raises the nutrition health-care value of oat processed products, and has the potentials of preventing and treating hyperlipoidemia, hyperglycemia and other life-style related diseases and improving the gastrointestinal tract function.

This invention provides the sequence of 5,299 nucleotides from the E. canis genome. There are four proteins, ProA, ProB, MmpA, and a cytochrome oxidase homolog, as well as a partial lipoprotein signal peptidase homolog at the carboxy terminus, coded for in this cloned fragment. The antigenic properties of these proteins allow them to be used to create a vaccine. An embodiment of this invention includes the creation of a DNA vaccine, a recombinant vaccine, and a T cell epitope vaccine. Another embodiment of this invention includes the use of serological diagnosis techniques.

The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided.

Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and / or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

This invention provides compositions and methods related to the administration of psyllium husk, Î<2>-sitosterol, guggul tree extract, guar gum and chromium as a combination to reduce or control blood cholesterol, triglycerides, low density lipoproteins, blood sugar or increasing or controlling high density lipoproteins in a mammal, to reduce arterial plaque build-up, atherosclerosis, in a mammal which may be associated with cardiovascular, cerebrovascular, peripheral vascular, or intestinal vascular disorders.